SPRB

Spruce Biosciences, Inc. (SPRB) | Rumor.io

Spruce Biosciences

SPRB

Attention (50-day avg)0%

Attention rank (50-day avg)#1,970

Bullish sentiment (50-day avg)63%

Price to earnings ratio-0.94

Market capitalization136.5M

Earnings per share-38.4

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-39M

Social

What share of all stock conversation is about SPRB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0.01% +0.01

Apr 22

$SPRB has the potential for a big snap-back rally today, with a 5-10x return possible.
The company now has enough cash for runway through 2027, and most upcoming bullish catalysts are in place.
$SPRB is undervalued at $52/share, with a potential 50% return in the next 90 days, based on the company's cash and asset value.

Generated by AI

Sentiment

Of the messages about SPRB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +30.77	71.43% +17.58	87.84% +17.08
Bearish	0%	0% -30.77	28.57% -17.58	12.16% -17.08

Bullish· Nov 5

$SPRB has a low float, which makes it prone to explosive price movements.
The company has a strong balance sheet with $316M in assets and $38M in cash, providing a solid foundation for growth.
$SPRB's price can potentially surge due to a squeeze, as indicated by the high stakes of short sellers and the stock's nano float.

Bearish· Oct 8

The company's recent private placement to fund next-gen enzyme therapy has led to a significant stock price drop of as much as -14.2% during the day.
The company's valuation is still considered too low, with some analysts suggesting a target price of $90-$110, which is a significant drop from its current price.
The company's recent issuance of common stock and warrants at a low exercise price has been criticized as a toxic financing move that dilutes the ownership of existing shareholders.

Generated by AI

Topics

Of the messages about SPRB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	93.33%	2.27%
Analysts	—	0%	0%	44.01%
Technical Analysis	—	0%	6.67%	0.55%
Macro	—	0%	0%	53.14%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0.02%

Announcements· Nov 7

Spruce Biosciences ($SPRB) has a potential bull case with 2,000 patients at $180,000 net pricing, implying $350M+ revenue and an EV of $1.2B-$2.5B.

Technical Analysis· Jan 6

$SPRB's price has gapped up over 100% and is currently trading above its open, but may be due for a reversal if it fails to hold its current level.
A potential breakout above $2.80 could lead to a continuation of the uptrend, with the 50% fib bounce at $2.50 being a key level to watch.
The stock's MACD histogram has crossed above the signal line, indicating a potential uptrend, but the bear flag on the daily chart suggests that the stock may be due for a pullback.

Generated by AI

Community

Of the messages about SPRB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	33.33%	52.94%	27.73%
Newcomers	100%	66.67%	47.06%	72.27%

Regulars· Mar 14

The company's stock price has been impacted by recent top-line results from clinical trials, with the stock closing down -84.38% and experiencing a 76% aftermarket drop.
Multiple analysts have downgraded their recommendations on Spruce Biosciences, with RBC downgrading to Sector Perform from Outperform, and SVB Leerink and Guggenheim downgrading to Market Perform from Outperform.
The company has enough cash on hand to support next phase of clinical trials, despite the recent setbacks, and the stock has a history of experiencing significant price movements.

Newcomers· Mar 25

The approval of Denali's treatment for Hunter's Syndrome is seen as a positive precedent for Spruce Biosciences, Inc., especially considering they share the same FDA approval process and CDMO.
The high relative volume on Spruce Biosciences, Inc. is attracting attention from momentum traders, with the stock experiencing a significant price increase.
The stock's chart is impressive, with the user expressing optimism about its potential, despite mixed views on the company.

Generated by AI

News

Citizens reiterates Spruce Biosciences stock rating on therapy lead

6d agoInvesting.com

Wall Street Analysts Are Bullish on Top Healthcare Picks

Detailed price information for Spruce Biosciences Inc (SPRB-Q) from The Globe and Mail including charting and trades.

11d agoThe Globe and Mail

Lake Street Initiates Spruce Biosciences at Buy With $149 Price Target

Spruce Biosciences (SPRB) has an average rating of buy and mean price target of $148, according to a

12d agoYahoo Finance

Citizens reiterates Spruce Biosciences stock rating on gene therapy approval

12d agoInvesting.com

Spruce Biosciences at H.C. Wainwright: BLA path comes into focus

13d agoInvesting.com

Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., September 08, 2026--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 2:00 p.m. ET in New York.

22d agoYahoo Finance

Also Discussed

Investors talking about SPRB also mention

#	Name	Attention
1	Reliance Global Group Inc.RELI	0%new
2	Disc Medicine, Inc.IRON	0%new
3	Abivax SAABVX	0.01%-0.01
4	Turbo Energy, S.A. American Depositary SharesTURB	0.01%new
5	Boqii Holding LimitedBQ	0%0
6	PMV Pharmaceuticals, Inc.PMVP	0%0
7	Bluejay Diagnostics Inc.BJDX	0%0
8	Neuphoria Therapeutics Inc.NEUP	0%0
9	Galecto Inc.GLTO	0%0
10	TRML - Tourmaline Bio, Inc.	——

Spruce Biosciences, Inc.

Healthcare
Biotechnology

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for rare neurological and endocrine disorders with significant unmet medical need. Its current portfolio centers on enzyme replacement and small-molecule programs designed to address serious diseases where treatment options are limited or inadequate. The company’s work includes therapies for conditions such as Sanfilippo Syndrome Type B and congenital adrenal hyperplasia, reflecting its emphasis on targeted medicines for underserved patient populations. Spruce Biosciences, Inc. operates in the biotechnology sector and participates in the broader rare-disease market, where specialized clinical development and regulatory expertise are essential to bringing therapies to patients. Headquartered in South San Francisco, California, the company is positioned as a development-stage biopharmaceutical business concentrated on advancing precision treatments for complex disorders.

Website

Location

611 Gateway Boulevard

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about SPRB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0.01% +0.01

Apr 22

$SPRB has the potential for a big snap-back rally today, with a 5-10x return possible.
The company now has enough cash for runway through 2027, and most upcoming bullish catalysts are in place.
$SPRB is undervalued at $52/share, with a potential 50% return in the next 90 days, based on the company's cash and asset value.

Generated by AI

Sentiment

Of the messages about SPRB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +30.77	71.43% +17.58	87.84% +17.08
Bearish	0%	0% -30.77	28.57% -17.58	12.16% -17.08

Bullish· Nov 5

$SPRB has a low float, which makes it prone to explosive price movements.
The company has a strong balance sheet with $316M in assets and $38M in cash, providing a solid foundation for growth.
$SPRB's price can potentially surge due to a squeeze, as indicated by the high stakes of short sellers and the stock's nano float.

Bearish· Oct 8

The company's recent private placement to fund next-gen enzyme therapy has led to a significant stock price drop of as much as -14.2% during the day.
The company's valuation is still considered too low, with some analysts suggesting a target price of $90-$110, which is a significant drop from its current price.
The company's recent issuance of common stock and warrants at a low exercise price has been criticized as a toxic financing move that dilutes the ownership of existing shareholders.

Generated by AI

Topics

Of the messages about SPRB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	93.33%	2.27%
Analysts	—	0%	0%	44.01%
Technical Analysis	—	0%	6.67%	0.55%
Macro	—	0%	0%	53.14%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0.02%

Announcements· Nov 7

Spruce Biosciences ($SPRB) has a potential bull case with 2,000 patients at $180,000 net pricing, implying $350M+ revenue and an EV of $1.2B-$2.5B.

Technical Analysis· Jan 6

$SPRB's price has gapped up over 100% and is currently trading above its open, but may be due for a reversal if it fails to hold its current level.
A potential breakout above $2.80 could lead to a continuation of the uptrend, with the 50% fib bounce at $2.50 being a key level to watch.
The stock's MACD histogram has crossed above the signal line, indicating a potential uptrend, but the bear flag on the daily chart suggests that the stock may be due for a pullback.

Generated by AI

Community

Of the messages about SPRB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	33.33%	52.94%	27.73%
Newcomers	100%	66.67%	47.06%	72.27%

Regulars· Mar 14

The company's stock price has been impacted by recent top-line results from clinical trials, with the stock closing down -84.38% and experiencing a 76% aftermarket drop.
Multiple analysts have downgraded their recommendations on Spruce Biosciences, with RBC downgrading to Sector Perform from Outperform, and SVB Leerink and Guggenheim downgrading to Market Perform from Outperform.
The company has enough cash on hand to support next phase of clinical trials, despite the recent setbacks, and the stock has a history of experiencing significant price movements.

Newcomers· Mar 25

The approval of Denali's treatment for Hunter's Syndrome is seen as a positive precedent for Spruce Biosciences, Inc., especially considering they share the same FDA approval process and CDMO.
The high relative volume on Spruce Biosciences, Inc. is attracting attention from momentum traders, with the stock experiencing a significant price increase.
The stock's chart is impressive, with the user expressing optimism about its potential, despite mixed views on the company.

Generated by AI

Spruce Biosciences

Social

Apr 22

Bullish· Nov 5

Bearish· Oct 8

Announcements· Nov 7

Technical Analysis· Jan 6

Regulars· Mar 14

Newcomers· Mar 25

Citizens reiterates Spruce Biosciences stock rating on therapy lead

Wall Street Analysts Are Bullish on Top Healthcare Picks

Lake Street Initiates Spruce Biosciences at Buy With $149 Price Target

Citizens reiterates Spruce Biosciences stock rating on gene therapy approval

Spruce Biosciences at H.C. Wainwright: BLA path comes into focus

Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Also Discussed

Spruce Biosciences, Inc.

Company Information

Location

Citizens reiterates Spruce Biosciences stock rating on therapy lead

Wall Street Analysts Are Bullish on Top Healthcare Picks

Lake Street Initiates Spruce Biosciences at Buy With $149 Price Target

Citizens reiterates Spruce Biosciences stock rating on gene therapy approval

Spruce Biosciences at H.C. Wainwright: BLA path comes into focus

Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Also Discussed

Social

Apr 22

Bullish· Nov 5

Bearish· Oct 8

Announcements· Nov 7

Technical Analysis· Jan 6

Regulars· Mar 14

Newcomers· Mar 25